Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology |
Bologna, Zuzana
(Vascular Biology Center, Medical College of Georgia, Augusta University)
Teoh, Jian-peng (Vascular Biology Center, Medical College of Georgia, Augusta University) Bayoumi, Ahmed S. (Vascular Biology Center, Medical College of Georgia, Augusta University) Tang, Yaoliang (Vascular Biology Center, Medical College of Georgia, Augusta University) Kim, Il-man (Vascular Biology Center, Medical College of Georgia, Augusta University) |
1 | Brame, A. L., Maguire, J. J., Yang, P. R., Dyson, A., Torella, R., Cheriyan, J., Singer, M., Glen, R. C., Wilkinson, I. B. and Davenport, A. P. (2015) Design, characterization and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 65, 834-840. DOI |
2 | Brunvand, H., Liu, G. L., Ma, X. L., Yue, T. L., Ruffolo, R. R., Jr. and Feuerstein, G. Z. (1998) SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. Eur. J. Pharmacol. 356, 193-198. DOI |
3 | DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G. D., Cowan, C. L., Graczyk, T. M., Chen, X. T., Pitis, P. M., Gotchev, D., Yuan, C., Koblish, M., Lark, M. W. and Violin, J. D. (2013) A G proteinbiased ligand at the -opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344, 708-717. DOI |
4 | Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K. and Xiao, R. P. (2001) Dual modulation of cell survival and cell death by -adrenergic signaling in adult mouse cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 98, 1607-1612. DOI |
5 | Ceraudo, E., Galanth, C., Carpentier, E., Banegas-Font, I., Schonegge, A. M., Alvear-Perez, R., Iturrioz, X., Bouvier, M. and Llorens-Cortes, C. (2014) Biased signaling favoring over -arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine. J. Biol. Chem. 289, 24599-24610. DOI |
6 | Burnier, M. and Brunner, H. R. (2000) Angiotensin II receptor antagonists. Lancet 355, 637-645. DOI |
7 | Butcher, A. J., Prihandoko, R., Kong, K. C., McWilliams, P., Edwards, J. M., Bottrill, A., Mistry, S. and Tobin, A. B. (2011) Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 286, 11506-11518. DOI |
8 | Byers, M. A., Calloway, P. A., Shannon, L., Cunningham, H. D., Smith, S., Li, F., Fassold, B. C. and Vines, C. M. (2008) Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. J. Immunol. 181, 4723-4732. DOI |
9 | Chandra, S. M., Razavi, H., Kim, J., Agrawal, R., Kundu, R. K., Perez, V. D., Zamanian, R. T., Quertermous, T. and Chun, H. J. (2011) Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 31, 814-820. DOI |
10 | Winpenny, D., Clark, M. and Cawkill, D. (2016) Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased opioid receptor agonists. Br. J. Pharmacol. 173, 1393-1403. DOI |
11 | Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K. and Lefkowitz, R. J. (2007) A unique mechanism of -blocker action: carvedilol stimulates -arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662. DOI |
12 | Xiang, Y. and Kobilka, B. K. (2003) Myocyte adrenoceptor signaling pathways. Science 300, 1530-1532. DOI |
13 | Woo, A. Y., Jozwiak, K., Toll, L., Tanga, M. J., Kozocas, J. A., Jimenez, L., Huang, Y., Song, Y., Plazinska, A., Pajak, K., Paul, R. K., Bernier, M., Wainer, I. W. and Xiao, R. P. (2014) Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of -adrenoceptor. J. Biol. Chem. 289, 19351-19363. DOI |
14 | Woo, A. Y., Wang, T. B., Zeng, X. K., Zhu, W. Z., Abernethy, D. R., Wainer, I. W. and Xiao, R. P. (2009) Stereochemistry of an agonist determines coupling preference of -adrenoceptor to different G proteins in cardiomyocytes. Mol. Pharmacol. 75, 158-165. DOI |
15 | Wright, J. J., Kim, J., Buchanan, J., Boudina, S., Sena, S., Bakirtzi, K., Ilkun, O., Theobald, H. A., Cooksey, R. C., Kandror, K. V. and Abel, E. D. (2009) Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc. Res. 82, 351-360. DOI |
16 | Xiao, R. P. and Balke, C. W. (2004) / exchange linking -adrenergic Gi signaling to heart failure: associated defect of adrenergic contractile support. J. Mol. Cell. Cardiol. 36, 7-11. DOI |
17 | Tang, Y. P., Wang, Y. C., Park, K. M., Hu, Q. P., Teoh, J. P., Broskova, Z., Ranganathan, P., Jayakumar, C., Li, J., Su, H. B., Tang, Y. L., Ramesh, G. and Kim, I. M. (2015) MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc. Res. 106, 387-397. DOI |
18 | Ahn, S., Kim, J., Hara, M. R., Ren, X. R. and Lefkowitz, R. J. (2009) -arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J. Biol. Chem. 284, 8855-8856. DOI |
19 | Alonso, N., Zappia, C. D., Cabrera, M., Davio, C. A., Shayo, C., Monczor, F. and Fernandez, N. C. (2015) Physiological implications of biased signaling at histamine H2 receptors. Front. Pharmacol. 6, 45. |
20 | Takahashi, A., Kato, K., Kuboyama, A., Inoue, T., Tanaka, Y., Kuhara, A., Kinoshita, K., Takeda, S. and Wake, N. (2009) Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol. Oncol. 113, 270-276. DOI |
21 | Teoh, J. P., Park, K. M., Broskova, Z., Jimenez, F. R., Bayoumi, A. S., Archer, K., Su, H. B., Johnson, J., Weintraub, N. L., Tang, Y. and Kim, I. M. (2015) Identification of gene signatures regulated by carvedilol in mouse heart. Physiol. Genomics 47, 376-385. DOI |
22 | Teoh, J. P., Park, K. M., Wang, Y. C., Hu, Q. P., Kim, S., Wu, G. Y., Huang, S., Maihle, N. and Kim, I. M. (2014) Endothelin-1/Endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cell. Signal. 26, 2885-2895. DOI |
23 | Thompson, G. L., Kelly, E., Christopoulos, A. and Canals, M. (2015) Novel GPCR paradigms at the -opioid receptor. Br. J. Pharmacol. 172, 287-296. DOI |
24 | Salloum, F. N., Yin, C. and Kukreja, R. C. (2010) Role of microRNAs in cardiac preconditioning. J. Cardiovasc. Pharmacol. 56, 581-588. DOI |
25 | Rosethorne, E. M. and Charlton, S. J. (2011) Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits -arrestin without activating G proteins. Mol. Pharmacol. 79, 749-757. DOI |
26 | Rubin, J. B. (2009) Chemokine signaling in cancer: One hump or two? Semin. Cancer Biol. 19, 116-122. DOI |
27 | Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. and Masaki, T. (1990) Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 348, 732-735. DOI |
28 | Schorlemmer, A., Matter, M. L. and Shohet, R. V. (2008) Cardioprotective signaling by endothelin. Trends Cardiovasc. Med. 18, 233-239. DOI |
29 | Vanderbeld, B. and Kelly, G. M. (2000) New thoughts on the role of the gamma subunit in G protein signal transduction. Biochem. Cell Biol. 78, 537-550. |
30 | Tong, H., Bernstein, D., Murphy, E. and Steenbergen, C. (2005) The role of -adrenergic receptor signaling in cardioprotection. FASEB J. 19, 983-985. DOI |
31 | Rajagopal, K., Whalen, E. J., Violin, J. D., Stiber, J. A., Rosenberg, P. B., Premont, R. T., Coffman, T. M., Rockman, H. A. and Lefkowitz, R. J. (2006) -arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 103, 16284-16289. DOI |
32 | Muller, G. (2000) Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr. Med. Chem. 7, 861-888. DOI |
33 | Namkung, Y., Radresa, O., Armando, S., Devost, D., Beautrait, A., Le Gouill, C. and Laporte, S. A. (2016) Quantifying biased signaling in GPCRs using BRET-based biosensors. Methods 92, 5-10. DOI |
34 | Pradhan, A. A., Perroy, J., Walwyn, W. M., Smith, M. L., Vicente-Sanchez, A., Segura, L., Bana, A., Kieffer, B. L. and Evans, C. J. (2016) Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function. J. Neurosci. 36, 3541-3551. DOI |
35 | Quiat, D. and Olson, E. N. (2013) MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J. Clin. Invest. 123, 11-18. DOI |
36 | Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., Zwier, J. M., Deupi, X., Bron, P., Baneres, J. L., Mouillac, B. and Granier, S. (2012) Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 109, 6733-6738. DOI |
37 | Lefkowitz, R. J. (2013) Arrestins come of age: a personal historical perspective. Prog. Mol. Biol. Transl. Sci. 118, 3-18. |
38 | Schwarz, E. R., Kersting, P. H., Reffelmann, T., Meven, D. A., Al-Dashti, R., Skobel, E. C., Klosterhalfen, B. and Hanrath, P. (2003) Cardioprotection by Carvedilol: antiapoptosis is independent of -adrenoceptor blockage in the rat heart. J. Cardiovasc. Pharmacol. Ther. 8, 207-215. DOI |
39 | Scimia, M. C., Hurtado, C., Ray, S., Metzler, S., Wei, K., Wang, J. M., Woods, C. E., Purcell, N. H., Catalucci, D., Akasaka, T., Bueno, O. F., Vlasuk, G. P., Kaliman, P., Bodmer, R., Smith, L. H., Ashley, E., Mercola, M., Brown, J. H. and Ruiz-Lozano, P. (2012) APJ acts as a dual receptor in cardiac hypertrophy. Nature 488, 394-398. DOI |
40 | Shenoy, S. K., McDonald, P. H., Kohout, T. A. and Lefkowitz, R. J. (2001) Regulation of receptor fate by ubiquitination of activated -adrenergic receptor and -arrestin. Science 294, 1307-1313. DOI |
41 | Leurs, R., Chazot, P. L., Shenton, F. C., Lim, H. D. and de Esch, I. J. (2009) Molecular and biochemical pharmacology of the histamine H4 receptor. Br. J. Pharmacol. 157, 14-23. DOI |
42 | Nobles, K. N., Xiao, K. H., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T. Y., Bressler, E. A., Hara, M. R., Shenoy, S. K., Gygi, S. P. and Lefkowitz, R. J. (2011) Distinct phosphorylation sites on the -adrenergic receptor establish a barcode that encodes differential functions of -arrestin. Sci. Signal. 4, ra51. |
43 | Nevzorova, J., Evans, B. A., Bengtsson, T. and Summers, R. J. (2006) Multiple signalling pathways involved in -adrenoceptormediated glucose uptake in rat skeletal muscle cells. Br. J. Pharmacol. 147, 446-454. DOI |
44 | Nichols, G. A., Hillier, T. A., Erbey, J. R. and Brown, J. B. (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence and risk factors. Diabetes Care 24, 1614-1619. DOI |
45 | Nijmeijer, S., Vischer, H. F., Sirci, F., Schultes, S., Engelhardt, H., de Graaf, C., Rosethorne, E. M., Charlton, S. J. and Leurs, R. (2013) Detailed analysis of biased histamine receptor signalling by JNJ 7777120 analogues. Br. J. Pharmacol. 170, 78-88. DOI |
46 | Noma, T., Lemaire, A., Naga Prasad, S. V., Barki-Harrington, L., Tilley, D. G., Chen, J., Le Corvoisier, P., Violin, J. D., Wei, H., Lefkowitz, R. J. and Rockman, H. A. (2007) B-arrestin-mediated -adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458. DOI |
47 | Rankovic, Z., Brust, T. F. and Bohn, L. M. (2016) Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorg. Med. Chem. Lett. 26, 241-250. DOI |
48 | Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., DeWire, S. M., Violin, J. D. and Lefkowitz, R. J. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377. DOI |
49 | Rajagopal, S., Rajagopal, K. and Lefkowitz, R. J. (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386. DOI |
50 | Rane, S., He, M. Z., Sayed, D., Yan, L., Vatner, D. and Abdellatif, M. (2010) An antagonism between the AKT and -adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell. Signal. 22, 1054-1062. DOI |
51 | Eglen, R. M., Bosse, R. and Reisine, T. (2007) Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay Drug Dev. Technol. 5, 425-451. DOI |
52 | Doughty, R. N., Whalley, G. A., Walsh, H., Gamble, G., Sharpe, N. and Investigat, C. E. S. (2001) Effects of carvedilol on left ventricular remodelling in patients following acute myocardial infarction: The CAPRICORN echo substudy. Circulation 104, 517. |
53 | Dulin, B. and Abraham, W. T. (2004) Pharmacology of carvedilol. Am. J. Cardiol. 93, 3B-6B. |
54 | Dunn, C. J., Lea, A. P. and Wagstaff, A. J. (1997) Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54, 161-185. DOI |
55 | Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M. and Gogos, J. A. (2004) Convergent evidence for impaired AKT1-GSK3 signaling in schizophrenia. Nat. Genet. 36, 131-137. DOI |
56 | Ferguson, S. S. (2001) Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24. |
57 | McCloskey, D. T., Turcato, S., Wang, G. Y., Turnbull, L., Zhu, B. Q., Bambino, T., Nguyen, A. P., Lovett, D. H., Nissenson, R. A., Karliner, J. S. and Baker, A. J. (2008) Expression of a -coupled receptor in the heart causes impaired handling, myofilament injury and dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 294, H205-H212. DOI |
58 | Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. and Wuthrich, K. (2012) Biased signaling pathways in -adrenergic receptor characterized by -NMR. Science 335, 1106-1110. DOI |
59 | Luan, B., Zhao, J., Wu, H. Y., Duan, B. Y., Shu, G. W., Wang, X. Y., Li, D. S., Jia, W. P., Kang, J. H. and Pei, G. (2009) Deficiency of a -arrestin-2 signal complex contributes to insulin resistance. Nature 457, 1146-1149. DOI |
60 | Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F. T., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G. and Lefkowitz, R. J. (1999) -arrestin-dependent formation of (2) adrenergic receptor-Src protein kinase complexes. Science 283, 655-661. DOI |
61 | McDonald, P. H., Chow, C. W., Miller, W. E., Laporte, S. A., Field, M. E., Lin, F. T., Davis, R. J. and Lefkowitz, R. J. (2000) -arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574-1577. DOI |
62 | Hoffmann, C., Ziegler, N., Reiner, S., Krasel, C. and Lohse, M. J. (2008) Agonist-selective, receptor-specific interaction of human P2Y receptors with -arrestin-1 and -2. J. Biol. Chem. 283, 30933-30941. DOI |
63 | Follin-Arbelet, V., Torgersen, M. L., Naderi, E. H., Misund, K., Sundan, A. and Blomhoff, H. K. (2013) Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway. Cancer Lett. 335, 323-331. DOI |
64 | Free, R. B., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J. L., Padron, A., Meade, J. A., Xiao, J. B., Hu, X., Dulcey, A. E., Han, Y., Duan, L. H., Titus, S., Bryant-Genevier, M., Barnaeva, E., Ferrer, M., Javitch, J. A., Beuming, T., Shi, L., Southall, N. T., Marugan, J. J. and Sibley, D. R. (2014) Discovery and characterization of a G protein-biased agonist that inhibits -arrestin recruitment to the dopamine receptor. Mol. Pharmacol. 86, 96-105. DOI |
65 | Habata, Y., Fujii, R., Hosoya, M., Fukusumi, S., Kawamata, Y., Hinuma, S., Kitada, C., Nishizawa, N., Murosaki, S., Kurokawa, T., Onda, H., Tatemoto, K. and Fujino, M. (1999) Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta 1452, 25-35. DOI |
66 | Hamm, H. E. (1998) The many faces of G protein signaling. J. Biol. Chem. 273, 669-672. DOI |
67 | Hermans, E. (2003) Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol. Ther. 99, 25-44. DOI |
68 | Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., Nishimura, O. and Fujino, M. (2000) Molecular and functional characteristics of APJ - Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067. DOI |
69 | Ikeda, Y., Kumagai, H., Motozawa, Y., Suzuki, J. and Komuro, I. (2015) Biased agonism of the angiotensin II type I receptor a potential strategy for the rreatment of acute heart failure. Int. Heart J. 56, 485-488. DOI |
70 | Japp, A. G. and Newby, D. E. (2008) The apelin-APJ system in heart failure pathophysiologic relevance and therapeutic potential. Biochem. Pharmacol. 75, 1882-1892. DOI |
71 | Jean-Alphonse, F., Perkovska, S., Frantz, M. C., Durroux, T., Mejean, C., Morin, D., Loison, S., Bonnet, D., Hibert, M., Mouillac, B. and Mendre, C. (2009) Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 20, 2190-2203. DOI |
72 | Chong, K. S., Gardner, R. S., Morton, J. J., Ashley, E. A. and Mc-Donagh, T. A. (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 8, 355-360. DOI |
73 | Chen, X., Sassano, M. F., Zheng, L. Y., Setola, V., Chen, M., Bai, X., Frye, S. V., Wetsel, W. C., Roth, B. L. and Jin, J. (2012) Structurefunctional selectivity relationship studies of -arrestin-biased dopamine D-2 receptor agonists. J. Med. Chem. 55, 7141-7153. DOI |
74 | Chen, X. T., Pitis, P., Liu, G. D., Yuan, C., Gotchev, D., Cowan, C. L., Rominger, D. H., Koblish, M., DeWire, S. M., Crombie, A. L., Violin, J. D. and Yamashita, D. S. (2013) Structure-activity relationships and discovery of a G protein biased opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J. Med. Chem. 56, 8019-8031. DOI |
75 | Chesley, A., Lundberg, M. S., Asai, T., Xiao, R. P., Ohtani, S., Lakatta, E. G. and Crow, M. T. (2000) The -adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through -dependent coupling to phosphatidylinositol 3'-kinase. Circ. Res. 87, 1172-1179. DOI |
76 | Ciccarelli, M., Chuprun, J. K., Rengo, G., Gao, E., Wei, Z. Y., Peroutka, R. J., Gold, J. I., Gumpert, A., Chen, M., Otis, N. J., Dorn, G. W., Trimarco, B., Iaccarino, G. and Koch, W. J. (2011) G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 123, 1953-1962. DOI |
77 | Cipolletta, E., Campanile, A., Santulli, G., Sanzari, E., Leosco, D., Campiglia, P., Trimarco, B. and Iaccarino, G. (2009) The G protein coupled receptor kinase 2 plays an essential role in -adrenergic receptor-induced insulin resistance. Cardiovasc. Res. 84, 407-415. DOI |
78 | Aurora, A. B., Mahmoud, A. I., Luo, X., Johnson, B. A., van Rooij, E., Matsuzaki, S., Humphries, K. M., Hill, J. A., Bassel-Duby, R., Sadek, H. A. and Olson, E. N. (2012) MicroRNA-214 protects the mouse heart from ischemic injury by controlling overload and cell death. J. Clin. Invest. 122, 1222-1232. DOI |
79 | Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M. and Bouvier, M. (2000) Detection of -adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. U.S.A. 97, 3684-3689. |
80 | Aplin, M., Christensen, G. L., Schneider, M., Heydorn, A., Gammeltoft, S., Kjolbye, A. L., Sheikh, S. P. and Hansen, J. L. (2007) The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and Langendorff-perfused hearts. Basic Clin. Pharmacol. Toxicol. 100, 289-295. DOI |
81 | Yuan, Y. Y., Stevens, D. L., Braithwaite, A., Scoggins, K. L., Bilsky, E. J., Akbarali, H. I., Dewey, W. L. and Zhang, Y. (2012) -N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists. Bioorg. Med. Chem. Lett. 22, 4731-4734. DOI |
82 | Xiao, R. P., Ji, X. W. and Lakatta, E. G. (1995) Functional coupling of the -adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 47, 322-329. |
83 | Xiao, R. P., Zhang, S. J., Chakir, K., Avdonin, P., Zhu, W. Z., Bond, R. A., Balke, C. W., Lakatta, E. G. and Cheng, H. P. (2003) Enhanced signaling selectively negates -adrenergic receptor (AR)- but not -AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108, 1633-1639. DOI |
84 | Yu, Q. J., Si, R., Zhou, N., Zhang, H. F., Guo, W. Y., Wang, H. C. and Gao, F. (2008) Insulin inhibits -adrenergic action in ischemic/reperfused heart: a novel mechanism of insulin in cardioprotection. Apoptosis 13, 305-317. DOI |
85 | Zhang, Y., Williams, D. A., Zaidi, S. A., Yuan, Y. Y., Braithwaite, A., Bilsky, E. J., Dewey, W. L., Akbarali, H. I., Streicher, J. M. and Selley, D. E. (2016) 17-cyclopropylmethyl-3, -dihydroxy-4,-epoxy--(4'-pyridylcarboxamido)morphinan (NAP) modulating the mu opioid receptor in a biased fashion. ACS Chem. Neurosci. 7, 297-304. DOI |
86 | Zhou, L., Lovell, K. M., Frankowski, K. J., Slauson, S. R., Phillips, A. M., Streicher, J. M., Stahl, E., Schmid, C. L., Hodder, P., Madoux, F., Cameron, M. D., Prisinzano, T. E., Aube, J. and Bohn, L. M. (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J. Biol. Chem. 288, 36703-36716. DOI |
87 | Boerrigter, G., Lark, M. W., Whalen, E. J., Soergel, D. G., Violin, J. D. and Burnett, J. C., Jr. (2011) Cardiorenal actions of TRV120027, a novel -arrestin-biased ligand at the angiotensin II yype I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ. Heart Fail. 4, 770-778. DOI |
88 | Bagnato, A., Salani, D., Di Castro, V., Wu-Wong, J. R., Tecce, R., Nicotra, M. R., Venuti, A. and Natali, P. G. (1999) Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth. Cancer Res. 59, 720-727. |
89 | Beaulieu, J. M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R. and Caron, M. G. (2005) An Akt/-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273. DOI |
90 | Bockaert, J. and Pin, J. P. (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18, 1723-1729. DOI |
91 | Violin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M. and Lark, M. W. (2010) Selectively engaging -arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335, 572-579. DOI |
92 | Viscusi, E., Minkowitz, H., Webster, L., Soergel, D., Burt, D., Subach, R. and Skobieranda, F. (2016) Rapid reduction in pain intensity with oliceridine (TRV130), a novel receptor G protein Pathway Selective modulator (-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trials. J. Pain 17, S82-S83. |
93 | Williams, D. L., Jr., Jones, K. L., Colton, C. D. and Nutt, R. F. (1991) Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem. Biophys. Res. Commun. 180, 475-480. DOI |
94 | Shimizu, I., Minamino, T., Toko, H., Okada, S., Ikeda, H., Yasuda, N., Tateno, K., Moriya, J., Yokoyama, M., Nojima, A., Koh, G. Y., Akazawa, H., Shiojima, I., Kahn, C. R., Abel, E. D. and Komuro, I. (2010) Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120, 1506-1514. DOI |
95 | Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M. H., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L. and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors. Science 340, 615-619. DOI |
96 | Wang, X. H., Ha, T. Z., Zou, J. H., Ren, D. Y., Liu, L., Zhang, X., Kalbfleisch, J., Gao, X., Williams, D. and Li, C. F. (2014) MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. Cardiovasc. Res. 102, 385-395. DOI |
97 | Wess, J. (1997) G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J. 11, 346-354. DOI |
98 | White, K. L., Robinson, J. E., Zhu, H., DiBerto, J. F., Polepally, P. R., Zjawiony, J. K., Nichols, D. E., Malanga, C. J. and Roth, B. L. (2015) The G protein-biased -opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J. Pharmacol. Exp. Ther. 352, 98-109. |
99 | Shukla, A. K., Xiao, K. H. and Lefkowitz, R. J. (2011) Emerging paradigms of -arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36, 457-469. DOI |
100 | Shukla, A. K., Violin, J. D., Whalen, E. J., Gesty-Palmer, D., Shenoy, S. K. and Lefkowitz, R. J. (2008) Distinct conformational changes in -arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. U.S.A. 105, 9988-9993. DOI |
101 | Skiba, N. P., Bae, H. and Hamm, H. E. (1996) Mapping of effector binding sites of transducin -subunit using / chimeras. J. Biol. Chem. 271, 413-424. DOI |
102 | Soergel, D. G., Subach, R. A., Sadler, B., Connell, J., Marion, A. S., Cowan, C. L., Violin, J. D. and Lark, M. W. (2014) First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J. Clin. Pharmacol. 54, 351-357. DOI |
103 | Song, X. F., Coffa, S., Fu, H. A. and Gurevich, V. V. (2009) How does arrestin assemble MAPKs into a signaling complex? J. Biol. Chem. 284, 685-695. DOI |
104 | Song, X. S., Zheng, X. L., Malbon, C. C. and Wang, H. Y. (2001) enhances in vivo activation of and insulin signaling to GLUT4. J. Biol. Chem. 276, 34651-34658. DOI |
105 | Spinella, F., Rosano, L., Di Castro, V., Nicotra, M. R., Natali, P. G. and Bagnato, A. (2004) Inhibition of cyclooxygenase-1 and-2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin. Cancer Res. 10, 4670-4679. DOI |
106 | Rodefeld, M. D., Beau, S. L., Schuessler, R. B., Boineau, J. P. and Saffitz, J. E. (1996) -adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high -adrenergic receptor density. J. Cardiovasc. Electrophysiol. 7, 1039-1049. DOI |
107 | Rashid, A. J., So, C. H., Kong, M. M. C., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F. and George, S. R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of /11 in the striatum. Proc. Natl. Acad. Sci. U.S.A. 104, 654-659. DOI |
108 | Reinartz, M. T., Kalble, S., Littmann, T., Ozawa, T., Dove, S., Kaever, V., Wainer, I. W. and Seifert, R. (2015) Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the -adrenoceptor. Naunyn Schmiedebergs Arch. Pharmacol. 388, 51-65. DOI |
109 | Rives, M. L., Rossillo, M., Liu-Chen, L. Y. and Javitch, J. A. (2012) 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased -opioid receptor agonist that inhibits arrestin recruitment. J. Biol. Chem. 287, 27050-27054. DOI |
110 | Rosano, L., Cianfrocca, R., Tocci, P., Spinella, F., Di Castro, V., Spadaro, F., Salvati, E., Biroccio, A. M., Natali, P. G. and Bagnato, A. (2013a) -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced -catenin signaling. Oncogene 32, 5066-5077. DOI |
111 | Rosano, L., Spinella, F. and Bagnato, A. (2013b) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13, 637-651. DOI |
112 | Mochizuki, M., Yano, M., Oda, T., Tateishi, H., Kobayashi, S., Yamamoto, T., Ikeda, Y., Ohkusa, T., Ikemoto, N. and Matsuzaki, M. (2007) Scavenging free radicals by low-dose carvedilol prevents redox-dependent leak via stabilization of ryanodine receptor in heart failure. J. Am. Coll. Cardiol. 49, 1722-1732. DOI |
113 | McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J., Henderson, G. and Kelly, E. (2010) -opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol. Pharmacol. 78, 756-766. DOI |
114 | Milligan, G. (2004) Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. Eur. J. Pharm. Sci. 21, 397-405. DOI |
115 | Miura, S., Okabe, A., Matsuo, Y., Karnik, S. S. and Saku, K. (2013) Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens. Res. 36, 134-139. DOI |
116 | Overington, J. P., Al-Lazikani, B. and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996. DOI |
117 | O'Dowd, B. F., Heiber, M., Chan, A., Heng, H. H., Tsui, L. C., Kennedy, J. L., Shi, X. M., Petronis, A., George, S. R. and Nguyen, T. (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355-360. DOI |
118 | Ohsawa, Y. and Hirasawa, N. (2012) The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via antipruritic and anti-inflammatory effects in NC/Nga mice. Allergy 67, 1014-1022. DOI |
119 | Ohtsuka, T., Hamada, M., Hiasa, G., Sasaki, O., Suzuki, M., Hara, Y., Shigematsu, Y. and Hiwada, K. (2001) Effect of -blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 37, 412-417. DOI |
120 | Park, S. M., Chen, M., Schmerberg, C. M., Dulman, R. S., Rodriguiz, R. M., Caron, M. G., Jin, J. and Wetsel, W. C. (2016) Effects of -arrestin-biased dopamine D2 receptor ligands on schizophrenialike behavior in hypoglutamatergic mice. Neuropsychopharmacology 41, 704-715. DOI |
121 | Perrino, C. and Rockman, H. A. (2007) Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Curr. Opin. Cardiol. 22, 443-449. DOI |
122 | Morris, A. J. and Malbon, C. C. (1999) Physiological regulation of G protein-linked signaling. Physiol. Rev. 79, 1373-1430. DOI |
123 | Rosano, L., Spinella, F., Di Castro, V., Nicotra, M. R., Dedhar, S., de Herreros, A. G., Natali, P. G. and Bagnato, A. (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 65, 11649-11657. DOI |
124 | Fu, Q., Xu, B., Liu, Y. M., Parikh, D., Li, J., Li, Y., Zhang, Y., Riehle, C., Zhu, Y., Rawlings, T., Shi, Q., Clark, R. B., Chen, X. W., Abel, E. D. and Xiang, Y. K. (2014) Insulin inhibits cardiac contractility by inducing a -biased -adrenergic signaling in hearts. Diabetes 63, 2676-2689. DOI |
125 | Kenakin, T. and Christopoulos, A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216. |
126 | Kilts, J. D., Gerhardt, M. A., Richardson, M. D., Sreeram, G., Mackensen, G. B., Grocott, H. P., White, W. D., Davis, R. D., Newman, M. F., Reves, J. G., Schwinn, D. A. and Kwatra, M. M. (2000) -adrenergic and several other G protein-coupled receptors in human atrial membranes activate both and . Circ. Res. 87, 705-709. DOI |
127 | Kim, I. M., Tilley, D. G., Chen, J., Salazar, N. C., Whalen, E. J., Violin, J. D. and Rockman, H. A. (2008) -blockers alprenolol and carvedilol stimulate -arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. U.S.A. 105, 14555-14560. DOI |
128 | Kim, I. M., Wang, Y. C., Park, K. M., Tang, Y. P., Teoh, J. P., Vinson, J., Traynham, C. J., Pironti, G., Mao, L., Su, H. B., Johnson, J. A., Koch, W. J. and Rockman, H. A. (2014) -arrestin1-biased -adrenergic receptor signaling regulates microRNA processing. Circ. Res. 114, 833-844. DOI |
129 | Molinari, P., Vezzi, V., Sbraccia, M., Gro, C., Riitano, D., Ambrosio, C., Casella, I. and Costa, T. (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. J. Biol. Chem. 285, 12522-12535. DOI |
130 | Morisco, C., Lembo, G. and Trimarco, B. (2006) Insulin resistance and cardiovascular risk: new insights from molecular and cellular biology. Trends Cardiovasc. Med. 16, 183-188. DOI |
131 | Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L. and Trejo, J. (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration and invasion of breast cancer cells. Cancer Res. 66, 307-314. DOI |
132 | Daaka, Y., Luttrell, L. M. and Lefkowitz, R. J. (1997) Switching of the coupling of the -adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88-91. DOI |
133 | Pitkin, S. L., Maguire, J. J., Bonner, T. I. and Davenport, A. P. (2010) International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology and function. Pharmacol. Rev. 62, 331-342. DOI |
134 | Pope, G. R., Roberts, E. M., Lolait, S. J. and O'Carroll, A. M. (2012) Central and peripheral apelin receptor distribution in the mouse: species differences with rat. Peptides 33, 139-148. DOI |
135 | Cognetti, F., Bagnato, A., Colombo, N., Savarese, A., Scambia, G., Sehouli, J., Wimberger, P., Sorio, R., Harter, P., Mari, E., McIntosh, S., Nathan, F., Pemberton, K. and Baumann, K. (2013) A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14) Gynecol. Oncol. 130, 31-37. DOI |
136 | Conroy, J. L., Free, R. B. and Sibley, D. R. (2015) Identification of G protein-biased agonists that fail to recruit -arrestin or promote internalization of the D1 dopamine receptor. ACS Chem. Neurosci. 6, 681-692. DOI |
137 | Cook, S. A., Varela-Carver, A., Mongillo, M., Kleinert, C., Khan, M. T., Leccisotti, L., Strickland, N., Matsui, T., Das, S., Rosenzweig, A., Punjabi, P. and Camici, P. G. (2010) Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 31, 100-111. DOI |
138 | DeWire, S. M., Ahn, S., Lefkowitz, R. J. and Shenoy, S. K. (2007) -arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510. DOI |
139 | Gether, U. (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90-113. DOI |
140 | Gautam, N., Downes, G. B., Yan, K. and Kisselev, O. (1998) The G-protein gamma complex. Cell. Signal. 10, 447-455. DOI |
141 | Gong, K. Z., Li, Z. J., Xu, M., Du, J. H., Lv, Z. Z. and Zhang, Y. Y. (2008) A novel protein kinase A-independent, -arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by -adrenergic receptors. J. Biol. Chem. 283, 29028-29036. DOI |
142 | Groer, C. E., Schmid, C. L., Jaeger, A. M. and Bohn, L. M. (2011) Agonist-directed interactions with specific -arrestins determine muopioid receptor trafficking, ubiquitination and dephosphorylation. J. Biol. Chem. 286, 31731-31741. DOI |
143 | Guil, S. and Caceres, J. F. (2007) The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat. Struct. Mol. Biol. 14, 591-596. DOI |
144 | Guleng, B., Tateishi, K., Ohta, M., Kanai, F., Jazag, A., Ijichi, F., Tanaka, Y., Washida, M., Morikane, K., Fukushima, Y., Yamori, T., Tsuruo, T., Kawabe, T., Miyagishi, M., Taira, K., Sata, M. and Omata, M. (2005) Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res. 65, 5864-5871. DOI |
145 | Lefkowitz, R. J. (1998) G protein-coupled receptors III. New roles for receptor kinases and -arrestins in receptor signaling and desensitization. J. Biol. Chem. 273, 18677-18680. DOI |
146 | Kim, J., Ahn, S., Ren, X. R., Whalen, E. J., Reiter, E., Wei, H. J. and Lefkowitz, R. J. (2005) Functional antagonism of different G protein-coupled receptor kinases for -arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 102, 1442-1447. DOI |
147 | Lee, Y., Ahn, C., Han, J. J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., Kim, S. and Kim, V. N. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419. DOI |